Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)

Recruiting in Palo Alto (17 mi)

+20 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Medical College of Wisconsin

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Blood stem cell transplants are one treatment option for people with lymphoma or other types of blood cancers. For this type of treatment, family members or unrelated donors with a similar tissue type usually donate their blood stem cells to the transplant patients. This study will evaluate the effectiveness of a type of blood stem cell transplant that uses lower doses of chemotherapy in people with relapsed follicular non-Hodgkin's lymphoma (NHL).

Research Team

Mary Horowitz, MD, MS

Principal Investigator

Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin

Eligibility Criteria

Inclusion Criteria

Histologically confirmed World Health Organization (WHO) classification CD20+ follicular lymphoma grades 1, 2, or 3a.

For either classification, the diffuse component of large cleaved cells (if present) cannot be greater than 50% of cellularity. Patients do not have to express t(14;18) to be eligible.

Any number of prior regimens (including autologous hematopoietic cell transplantation [HCT]); the most recent prior regimen must have occurred more than 28 days before study entry

Treatment Details

Interventions

• Hematopoietic Stem Cell Transplant (Stem Cell Transplant)
• Low Dose Chemotherapy (Chemotherapy)

Participant Groups

Group I: Hematopoietic Stem Cell Transplant Experimental Treatment 1 Intervention

Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.

Who Is Running the Clinical Trial?

Medical College of Wisconsin

Lead Sponsor

Trials

645

Recruited

1,180,000+

Dr. Joseph E. Kerschner

Medical College of Wisconsin

Chief Medical Officer since 2011

MD, specific institution not identified

Dr. John R. Raymond, Sr.

Medical College of Wisconsin

Chief Executive Officer since 2010

MD from the Medical University of South Carolina

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials

3,987

Recruited

47,860,000+

Dr. Gary H. Gibbons

National Heart, Lung, and Blood Institute (NHLBI)

Chief Executive Officer since 2012

MD from Harvard Medical School

Dr. James P. Kiley

National Heart, Lung, and Blood Institute (NHLBI)

Chief Medical Officer since 2011

MD from University of California, San Francisco

Blood and Marrow Transplant Clinical Trials Network

Collaborator

Trials

51

Recruited

14,600+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School

National Marrow Donor Program

Collaborator

Trials

63

Recruited

202,000+

Amy Ronneberg

National Marrow Donor Program

Chief Executive Officer since 2020

MBA from Capella University, BBA in Accounting from University of Wisconsin-Eau Claire

Steven Devine

National Marrow Donor Program

Chief Medical Officer

MD